Medtronic Statistics

Medtronic Statistics and Facts

Medtronics PLC Statistics

Medical Device Industry/Brands

  • Type of Business


  • Establishment Year


  • Headquarters



    ~90,000 (April 2022)

  • CEO

    Mr. Geoffrey Straub Martha (Chairman and Chief Executive Officer)

  • Industry

    Biotechnology, Health Care, Health Diagnostics, Manufacturing, Medical, Medical Device, and Therapeutics.

  • Revenue

    US$ 31,686 Mn (2021)

  • Products

    Advanced surgical technology, Cardiac rhythm, Cardiovascular, Diabetes, Ear, nose and throat, General surgery, Neurological, patient monitoring, and Other products.

  • Subsidiaries

    Intersect ENT, Mazor Robotics, HeartWare International Inc., MiniMed Distribution Corp, Medtronic Korea Co., Ltd., Given Imaging, Auto Suture do Brasil Ltda., Titan Spine, Inc., Osteotech, Inc., Medtronic of Canada Ltd, Medtronic Japan Co., Ltd., Visualase, Inc., super dimension, Inc., Covidien L.P., Medtronic CoreValve LLC, and Other Subsidiaries.

  • Competitors

    Thermo Fisher Scientific Inc., Danaher Corp., Siemens Healthineers AG, EssilorLuxottica SA, Becton, Dickinson and Co., Koninklijke Philips NV, Stryker Corp., Baxter International, Inc., Henry Schein, Inc., and others

  • Website

  • Brands

    Accu-Temp, ACT Plus, Adapta, Atlantis, autoLog, BioGlide, CapSure, Cardioblate, CD Horizon, Cornerstone-SR Channel, ClearView, Endo-Ring, Colorado, Enterram, ForSite, Freestyle, Hancock, InSync, InterStim, INVISx, Kappa 900, Keracel, LandmarX, MacroPore, Mattrix, Mdtronic, Meniett, Merocel, MeroGel, MeroPack, METRIX, MicroFrance, MRI Safety, MurphyScope, NeuroPEN, and other Brands.

Medtronic Statistics and Facts: This is a medical technology firm that develops, manufactures, distributes, and sells medical devices and related services. It is divided into the following sections: Groups for Restorative Therapies, Minimally Invasive Technologies, Cardiac and Vascular Groups, and Diabetes Products in the Cardiac and Vascular Group can be used to diagnose, treat, and manage cardiac rhythm disorders and other cardiovascular diseases.

The Minimally Invasive Technologies Group focuses on the gastrointestinal system, respiratory system, renal system, and lungs. It also includes diseases of the kidneys, pelvic region, and obesity. Neurostimulation and drug delivery systems are provided by the Restorative Therapies Group to treat chronic pain. It also treats issues with the spine, brain, pelvic health, and ear, throat, nose, and neck conditions. The Diabetes Group segment provides a continuous glucose monitoring system and consumables for insulin pumps. The company was established in 1949. It is headquartered in Dublin in, Ireland.

Medtronic is a global company and has experienced increases in its revenue. Medtronic PLC has seen a dramatic increase in its workforce since 2006. This has seen an increase in its total assets since 2014. These increases are due to Medtronic’s acquisition of Covidien, an Irish medical device company, in 2015.

Medtronic ranks among the top global companies in medical technology. A company’s success is measured by how many product approvals it has among its medical technology partners. The company with the highest number of product approvals and clearances of any top medical technology company in 2017. Medtronic is one of the 10 most valuable healthcare brands in the world, which is a measure of its success.

Overview Analysis of Business Segments:


The Cardiovascular includes Cardiac Rhythm & Heart failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular sections. The primary medical specialists who Medtronic Cardiovascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular, cardiothoracic, and vascular surgeons, and interventional cardiologists and radiologists.

Cardiac Rhythm & Heart Failure

The Medtronic Cardiac Rhythm & Heart Failure Division includes the following Operating Units. Cardiac Rhythm Management and Cardiac Ablation Solutions. Cardiovascular Diagnostics. Mechanical Circulatory Support. This division design manufactures and markets products that can be used to diagnose, treat, and manage heart rhythm disorders and heart disease. Medtronic Products include implantable devices, leads, delivery systems, products to treat atrial fibrillation (A.F.), products that reduce surgical site infections, information systems to manage patients with Cardiac Rhythm & Heart failure devices, as well as integrated health solutions.

Structural Heart & Aortic

Structural Heart & Aortic division includes the following Operating Units: Structural Heart & Aortic and Cardiac Surgery. The division includes therapies to treat heart valve disorders and aortic disease. Devices include products for the repair and replacement of perfusion systems, heart valves, positioning and stabilization systems for beating heart surgical ablation products, revascularization surgery, and a comprehensive line of products and therapies to treat aortic diseases such as aneurysms, dissections, and transections.

Coronary & Peripheral Vascular

The Coronary & Peripheral Vascular division comprises the following Operating Units. This division includes a wide range of therapies and products to treat both coronary artery disease and peripheral vascular disease. Products include coronary devices and related delivery systems. These include a wide range of catheters for angioplasty, guide catheters and wires, diagnostic catheters, peripheral drug-coated balloons, stents, angioplasty systems, and carotid protection systems for the treatment and prevention of vascular disease beyond the heart, as well as products for deep and superficial venous diseases.


Surgical Innovations

The Surgical Innovations division comprises the following Operating Units: Surgical Robotics and Surgical Innovations. This division design manufactures and markets advanced surgical products such as surgical stapling, vessel sealing instruments, and wound closure.

Respiratory, Gastrointestinal, & Renal

The Respiratory, Gastrointestinal, and Renal Division includes the following Operating Units. Respiratory Interventions. Patient Monitoring. Gastrointestinal. Renal Care Solutions. This division designs, manufactures, markets, and supports products in the emerging fields for minimally invasive gastrointestinal diagnostics and therapies, patient monitors, gastric and renal care solutions, as well as respiratory interventions, including airway management, ventilation therapies, and treatment of renal disease.


The Neuroscience divisions include Cranial & Spinal Technologies and Specialty Therapies. This group includes spinal surgeons and neurosurgeons, neurologists and pain management specialists, as well as anesthesiologists and orthopedic surgeons. Urologists, urogynecologists, and interventional radiologists are also among the primary medical specialists that use its products.

Cranial & Spinal Technologies

The Cranial & Spinal Technologies division, Operating Unit, develops, manufactures, and markets a complete portfolio of surgical devices and therapies. These devices are designed to increase the precision and workflow of neuro procedures and a range of medical devices and implants used in the treatment and rehabilitation of the spine. This division offers biologic solutions to the dental and orthopedic markets. It also offers highly differentiated imaging, navigation and power instruments, nerve monitoring, as well as robotic guidance systems for spine and cranial procedures.

Specialty Therapies

The Specialty Therapies division comprises the following Operating Units. This division creates, manufactures, and markets therapies and products to treat diseases such as ENT and patients with Acute Ischemic or Hemorrhagic Stroke. It also helps control overactive bladder, non-obstructive urinary retention, chronic fecal leakage, and other issues.


The Neuromodulation division and Operating Unit designs manufacture, and market spinal cord stimulation systems, implantable drug infusion systems for chronic pain, and other interventional products.

Diabetes Operating

The Diabetes Operating Unit designs manufacture and markets products and services to manage Type 1 and Type 2 Diabetes. Endocrinologists are the primary doctors who prescribe and use Diabetes products.

Medtronic Statistics:

Medtronic Total Revenue 2012-2021

Medtronic’s revenue has risen from 11.3 billion U.S. Dollars in 2006 to more than 31 million U.S. Dollars in 2021. Medtronic, medical technology and research firm work in many specialties, including diabetes and cardiovascular. It currently generates the majority of its revenue in the United States. Medtronic’s legal headquarter was moved to Dublin, Ireland in 2015, but this was due to tax reasons.

Medtronic Net Income 2012-2021

This graph shows Medtronic’s net revenue for the fiscal years 2012-2021. Medtronic Inc., a U.S.-based medical technology company, is listed here.  The company’s net income was 3.6 billion U.S. Dollars in 2021

Distribution of Medtronic Revenue by Segment 2018-2021

This statistic shows the revenue distribution for Medtronic in fiscal years 2018-2021. It is sorted by segment. Medtronic Inc., a U.S-Irish medical tech company, is Medtronic Inc. The company’s cardiovascular segment accounted for more than 10.7 billion U.S. Dollars in revenue in 2021.

Medtronic Medical-Surgical Net Sales Worldwide 2015-2020, by Market

This statistic shows the worldwide net sales of Medtronic’s minimally invasive therapy group from 2015 to 2021. It is sorted by market. Medtronic’s minimally-invasive therapies group had a total net sales figure of nearly 8.4 billion U.S. Dollars in 2021. The U.S. market accounted for approximately 3.6 billion.

Medtronic Revenue by Market 2018-2021

This chart shows the combined net sales of Medtronic between 2018 and 2021, sorted by market. Medtronic plc, an Irish medical technology company, is headquartered in Dublin (Ireland) and Minneapolis (Minnesota). The data shows that Medtronic’s U.S. Market Value in 2021 was more than 15.5 billion U.S. Dollars.

Medtronic Recent Developments:

The year 2022

  • In May, Medtronic acquired a 100% stake in Intersect ENT for US$1.1 billion.
  • In January, Medtronic acquired Affero, a medical technology company.
  • In January, Medtronic received US FDA approval for its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator to treat chronic pain associated with diabetic peripheral neuropathy.
  • In April, Medtronic acquired a portfolio of cardiac-device products from Acutus Medical Inc.
  • In May, Medtronic announced its plans to sell Intersect ENT’s subsidiary Fiagon to Hemostasis.

The year 2021

  • In August, Medtronic secured approval from U.S. Food & Drug Administration for its self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system.
  • In October, Medtronic’s subsidiary, Medtronic Canada ULC, launched Mazor X System for robotic-guided spine surgery.
  • In September, Medtronic entered into a collaboration agreement with Mpirik to provide disparities in care associated with sudden cardiac arrest.
  • In September, Medtronic launched new spiral technologies, Catalyft PL and PL40, Space-D Access System, and Accelerate Graft Delivery System with Grafton DBF.
  • In January, Medtronic received US FDA premarket approval of its Diamondtemp Ablation system for the treatment of patients with recurrent, symptomatic paroxysmal atrial fibrillation.
  • In March, Medtronic, along with other investors, invested US$7 million in BurnAlong.
  • In April, Medtronic’s subsidiary Medtronic Foundation and Children’s HeartLink announced a US$2.5 million, three-year, outcomes-based partnership on health equity for 10,000 children and 10,000 health workers in underserved countries.
  • In April, Medtronic established a new Medtronic Engineering and Innovation Center in Hyderabad, Telangana, India.
  • In April, Medtronic and Surgical Theater entered into a partnership to offer an augmented reality platform for cranial procedures.
  • In April, Medtronic secured the U.S. Food and Drug Administration’s breakthrough device designation status for the Imprint ablation catheter kit to treat malignant lesions in the lung
  • In May, Medtronic secured the CE Mark approval for its Evolut PRO+ TAVI System to treat people with severe aortic stenosis treatment system in Europe.
  • In June, Medtronic received the U.S. Food & Drug Administration’s expanded sanction for the Arctic Front of Cardiac Cryoablation Catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation.
  • In May, Medtronic and Medtronic Foundation entered into a partnership to address COVID-19 surges.
  • In May, Medtronic secured the C.E. mark approval for its InPen smart insulin pen for multiple daily injections.
  • In June, Medtronic secured US FDA approval for its Vanta, a recharge-free implantable neurostimulator platform.

Share This Statistics


Medical Device Industry/Brands Statistics and Facts


Pharmaceutical Industry/Brands Statistics and Facts